These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 24224693)

  • 1. Discovery of 1-(2,4-dichlorophenyl)-N-(piperidin-1-yl)-4-((pyrrolidine-1-sulfonamido)methyl)-5-(5-((4-(trifluoromethyl)phenyl)ethynyl)thiophene-2-yl)-1H-pyrazole-3-carboxamide as a novel peripherally restricted cannabinoid-1 receptor antagonist with significant weight-loss efficacy in diet-induced obese mice.
    Chang CP; Wu CH; Song JS; Chou MC; Wong YC; Lin Y; Yeh TK; Sadani AA; Ou MH; Chen KH; Chen PH; Kuo PC; Tseng CT; Chang KH; Tseng SL; Chao YS; Hung MS; Shia KS
    J Med Chem; 2013 Dec; 56(24):9920-33. PubMed ID: 24224693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of N-[(4R)-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-yl]-5-methyl-1H-pyrazole-3-carboxamide (MK-5596) as a novel cannabinoid-1 receptor (CB1R) inverse agonist for the treatment of obesity.
    Yan L; Huo P; Debenham JS; Madsen-Duggan CB; Lao J; Chen RZ; Xiao JC; Shen CP; Stribling DS; Shearman LP; Strack AM; Tsou N; Ball RG; Wang J; Tong X; Bateman TJ; Reddy VB; Fong TM; Hale JJ
    J Med Chem; 2010 May; 53(10):4028-37. PubMed ID: 20423086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of 1-(2,4-dichlorophenyl)-4-ethyl-5-(5-(2-(4-(trifluoromethyl)phenyl)ethynyl)thiophen-2-yl)-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide as a potential peripheral cannabinoid-1 receptor inverse agonist.
    Hung MS; Chang CP; Li TC; Yeh TK; Song JS; Lin Y; Wu CH; Kuo PC; Amancha PK; Wong YC; Hsiao WC; Chao YS; Shia KS
    ChemMedChem; 2010 Sep; 5(9):1439-43. PubMed ID: 20652930
    [No Abstract]   [Full Text] [Related]  

  • 4. Biarylpyrazolyl oxadiazole as potent, selective, orally bioavailable cannabinoid-1 receptor antagonists for the treatment of obesity.
    Lee SH; Seo HJ; Lee SH; Jung ME; Park JH; Park HJ; Yoo J; Yun H; Na J; Kang SY; Song KS; Kim MA; Chang CH; Kim J; Lee J
    J Med Chem; 2008 Nov; 51(22):7216-33. PubMed ID: 18954042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioisosteric replacement of the pyrazole 5-aryl moiety of N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A). A novel series of alkynylthiophenes as potent and selective cannabinoid-1 receptor antagonists.
    Tseng SL; Hung MS; Chang CP; Song JS; Tai CL; Chiu HH; Hsieh WP; Lin Y; Chung WL; Kuo CW; Wu CH; Chu CM; Tung YS; Chao YS; Shia KS
    J Med Chem; 2008 Sep; 51(17):5397-412. PubMed ID: 18712856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide (MK-0364), in rodents.
    Fong TM; Guan XM; Marsh DJ; Shen CP; Stribling DS; Rosko KM; Lao J; Yu H; Feng Y; Xiao JC; Van der Ploeg LH; Goulet MT; Hagmann WK; Lin LS; Lanza TJ; Jewell JP; Liu P; Shah SK; Qi H; Tong X; Wang J; Xu SS; Francis B; Strack AM; MacIntyre DE; Shearman LP
    J Pharmacol Exp Ther; 2007 Jun; 321(3):1013-22. PubMed ID: 17327489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tricyclic pyrazoles. 3. Synthesis, biological evaluation, and molecular modeling of analogues of the cannabinoid antagonist 8-chloro-1-(2',4'-dichlorophenyl)-N-piperidin-1-yl-1,4,5,6-tetrahydrobenzo[6,7]cyclohepta[1,2-c]pyrazole-3-carboxamide.
    Murineddu G; Ruiu S; Loriga G; Manca I; Lazzari P; Reali R; Pani L; Toma L; Pinna GA
    J Med Chem; 2005 Nov; 48(23):7351-62. PubMed ID: 16279795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel pyrazole derivatives as neutral CB₁ antagonists with significant activity towards food intake.
    Manca I; Mastinu A; Olimpieri F; Falzoi M; Sani M; Ruiu S; Loriga G; Volonterio A; Tambaro S; Bottazzi ME; Zanda M; Pinna GA; Lazzari P
    Eur J Med Chem; 2013 Apr; 62():256-69. PubMed ID: 23357307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the endocannabinoid/CB1 receptor system for treating obesity in Prader-Willi syndrome.
    Knani I; Earley BJ; Udi S; Nemirovski A; Hadar R; Gammal A; Cinar R; Hirsch HJ; Pollak Y; Gross I; Eldar-Geva T; Reyes-Capo DP; Han JC; Haqq AM; Gross-Tsur V; Wevrick R; Tam J
    Mol Metab; 2016 Dec; 5(12):1187-1199. PubMed ID: 27900261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Facile synthesis, ex-vivo and in vitro screening of 3-sulfonamide derivative of 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide (SR141716) a potent CB1 receptor antagonist.
    Kumar Srivastava B; Soni R; Patel JZ; Jha S; Shedage SA; Gandhi N; Sairam KV; Pawar V; Sadhwani N; Mitra P; Jain MR; Patel PR
    Bioorg Med Chem Lett; 2008 Jul; 18(14):3882-6. PubMed ID: 18585913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A critical review of both the synthesis approach and the receptor profile of the 8-chloro-1-(2',4'-dichlorophenyl)-N-piperidin-1-yl-1,4,5,6-tetrahydrobenzo[6,7]cyclohepta[1,2-c]pyrazole-3-carboxamide and analogue derivatives.
    Lazzari P; Distinto R; Manca I; Baillie G; Murineddu G; Pira M; Falzoi M; Sani M; Morales P; Ross R; Zanda M; Jagerovic N; Pinna GA
    Eur J Med Chem; 2016 Oct; 121():194-208. PubMed ID: 27240274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of 2-[5-(4-chloro-phenyl)-1-(2,4-dichloro-phenyl)-4-ethyl-1H-pyrazol-3-yl]-1,5,5-trimethyl-1,5-dihydro-imidazol-4-thione (BPR-890) via an active metabolite. A novel, potent and selective cannabinoid-1 receptor inverse agonist with high antiobesity efficacy in DIO mice.
    Wu CH; Hung MS; Song JS; Yeh TK; Chou MC; Chu CM; Jan JJ; Hsieh MT; Tseng SL; Chang CP; Hsieh WP; Lin Y; Yeh YN; Chung WL; Kuo CW; Lin CY; Shy HS; Chao YS; Shia KS
    J Med Chem; 2009 Jul; 52(14):4496-510. PubMed ID: 19530697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel selective antagonist of the cannabinoid CB1 receptor, MJ15, with prominent anti-obesity effect in rodent models.
    Chen W; Tang H; Liu H; Long L; Gong Z; Zheng J; Chi M; Xie Y; Zheng Z; Li S; Wang L
    Eur J Pharmacol; 2010 Jul; 637(1-3):178-85. PubMed ID: 20380831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NESS06SM reduces body weight with an improved profile relative to SR141716A.
    Mastinu A; Pira M; Pinna GA; Pisu C; Casu MA; Reali R; Marcello S; Murineddu G; Lazzari P
    Pharmacol Res; 2013 Aug; 74():94-108. PubMed ID: 23756200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioisosteric replacement of dihydropyrazole of 4S-(-)-3-(4-chlorophenyl)-N-methyl-N'-[(4-chlorophenyl)-sulfonyl]-4-phenyl-4,5-dihydro-1H-pyrazole-1-caboxamidine (SLV-319) a potent CB1 receptor antagonist by imidazole and oxazole.
    Srivastava BK; Soni R; Joharapurkar A; Sairam KV; Patel JZ; Goswami A; Shedage SA; Kar SS; Salunke RP; Gugale SB; Dhawas A; Kadam P; Mishra B; Sadhwani N; Unadkat VB; Mitra P; Jain MR; Patel PR
    Bioorg Med Chem Lett; 2008 Feb; 18(3):963-8. PubMed ID: 18207393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxadiazole-diarylpyrazole 4-carboxamides as cannabinoid CB1 receptor ligands.
    Lee SH; Seo HJ; Kim MJ; Kang SY; Song KS; Lee SH; Jung ME; Kim J; Lee J
    Bioorg Med Chem Lett; 2009 Apr; 19(7):1899-902. PubMed ID: 19269817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemical and biological investigation of cyclopropyl containing diaryl-pyrazole-3-carboxamides as novel and potent cannabinoid type 1 receptor antagonists.
    Szabó G; Varga B; Páyer-Lengyel D; Szemzo A; Erdélyi P; Vukics K; Szikra J; Hegyi E; Vastag M; Kiss B; Laszy J; Gyertyán I; Fischer J
    J Med Chem; 2009 Jul; 52(14):4329-37. PubMed ID: 19527048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SR147778 [5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide], a new potent and selective antagonist of the CB1 cannabinoid receptor: biochemical and pharmacological characterization.
    Rinaldi-Carmona M; Barth F; Congy C; Martinez S; Oustric D; Pério A; Poncelet M; Maruani J; Arnone M; Finance O; Soubrié P; Le Fur G
    J Pharmacol Exp Ther; 2004 Sep; 310(3):905-14. PubMed ID: 15131245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and biological evaluation of new N-alkyl 1-aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamides as cannabinoid receptor ligands.
    Silvestri R; Ligresti A; La Regina G; Piscitelli F; Gatti V; Lavecchia A; Brizzi A; Pasquini S; Allarà M; Fantini N; Carai MA; Bigogno C; Rozio MG; Sinisi R; Novellino E; Colombo G; Di Marzo V; Dondio G; Corelli F
    Eur J Med Chem; 2010 Dec; 45(12):5878-86. PubMed ID: 20943290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SLV330, a cannabinoid CB1 receptor antagonist, ameliorates deficits in the T-maze, object recognition and Social Recognition Tasks in rodents.
    de Bruin NM; Prickaerts J; Lange JH; Akkerman S; Andriambeloson E; de Haan M; Wijnen J; van Drimmelen M; Hissink E; Heijink L; Kruse CG
    Neurobiol Learn Mem; 2010 May; 93(4):522-31. PubMed ID: 20132903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.